ciglitazone has been researched along with Bone Loss, Osteoclastic in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bezafibrate treatment of mature osteoclast resulted in 50% inhibition (at 10(-8) M and 10(-7) M) of resorption, yet fenofibrate had no significant effect." | 1.34 | PPAR agonists modulate human osteoclast formation and activity in vitro. ( Buckley, KA; Chan, BY; Dillon, JP; Fraser, WD; Gallagher, JA; Gartland, A; Wilson, PJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, BY | 1 |
| Gartland, A | 1 |
| Wilson, PJ | 1 |
| Buckley, KA | 1 |
| Dillon, JP | 1 |
| Fraser, WD | 1 |
| Gallagher, JA | 1 |
1 other study available for ciglitazone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
PPAR agonists modulate human osteoclast formation and activity in vitro.
Topics: Acetates; Apoptosis; Bezafibrate; Bone Resorption; Butyrates; Cells, Cultured; Fenofibrate; Humans; | 2007 |